LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 232

Search options

  1. Book ; Online ; E-Book: Blood and marrow transplant handbook

    Maziarz, Richard T. / Schubach Slater, Susan

    comprehensive guide for patient care

    2021  

    Abstract: This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem ... ...

    Author's details Richard T. Maziarz, Susan Schubach Slater, editors
    Abstract This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant and cellular therapy patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook begins by providing a general overview of stem cell transplantation and goes on to outline disease-specific indications for stem cell transplantation. It then focuses on transplant complications and ongoing care, and finally explores cellular therapies for hematologic malignancies. Comprehensive and easy-to-use, Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care, Third Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers as well as residents, fellows, and other trainees who care for patients who undergo transplant and immune effector cell therapy.
    Keywords Hematopoietic stem cells/Transplantation ; Hematopoietic stem cells/Transplantation/Nursing ; Hematopoietic Stem Cell Transplantation/Nursing
    Subject code 617.44
    Language English
    Size 1 online resource (XX, 1006 p. 69 illus., 43 illus. in color.)
    Edition 3rd ed. 2021.
    Publisher Springer
    Publishing place Cham, Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 3-030-53626-2 ; 3-030-53625-4 ; 978-3-030-53626-8 ; 978-3-030-53625-1
    DOI 10.1007/978-3-030-53626-8
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book: Blood and marrow transplant handbook

    Maziarz, Richard T. / Slater, Susan

    comprehensive guide for patient care

    2015  

    Author's details Richard T. Maziarz ; Susan Slater
    Language English
    Size XIII, 444 S. : zahlr. Ill., graph. Darst., 203 mm x 127 mm
    Edition 2. ed.
    Publisher Springer
    Publishing place Cham u.a.
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT018639635
    ISBN 978-3-319-13831-2 ; 9783319138329 ; 3-319-13831-6 ; 3319138324
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Book: Blood and marrow transplant handbook

    Maziarz, Richard T. / Slater, Susan

    comprehensive guide for patient care

    2011  

    Author's details Richard T. Maziarz ; Susan Slater
    Language English
    Size XI, 200 S. : Ill., 203 mm x 127 mm
    Publisher Springer
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT016641447
    ISBN 978-1-4419-7505-8 ; 9781441975065 ; 1-4419-7505-5 ; 1441975063
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Article ; Online: The rationale behind grafting haploidentical hematopoietic stem cells.

    Maziarz, Richard T / Cook, Rachel J

    Hematology (Amsterdam, Netherlands)

    2024  Volume 29, Issue 1, Page(s) 2347673

    Abstract: The ability to perform hematopoietic cell transplant across major histocompatibility complex barriers can dramatically increase the availability of donors and allow more patients across the world to pursue curative transplant procedures for underlying ... ...

    Abstract The ability to perform hematopoietic cell transplant across major histocompatibility complex barriers can dramatically increase the availability of donors and allow more patients across the world to pursue curative transplant procedures for underlying hematologic disorders. Early attempts at haploidentical transplantation using broadly reactive T-cell depletion approaches were compromised by graft rejection, graft-versus-host disease and prolonged immune deficiency. The evolution of haploidentical transplantation focused on expanding transplanted hematopoietic progenitors as well as using less broadly reactive T-cell depletion. Significant outcome improvements were identified with technology advances allowing selective depletion of donor allospecific T cells, initially ex-vivo with evolution to its current in-vivo approach with the infusion of the highly immunosuppressive chemotherapy agent, cyclophosphamide after transplantation procedure. Current approaches are facile and portable, allowing expansion of allogeneic hematopoietic cell transplantation for patients across the world, including previously underserved populations.
    MeSH term(s) Humans ; Hematopoietic Stem Cell Transplantation/methods ; Transplantation, Haploidentical/methods ; Graft vs Host Disease/prevention & control ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cells/cytology
    Language English
    Publishing date 2024-05-07
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1341428-8
    ISSN 1607-8454 ; 1024-5332 ; 1024-5340
    ISSN (online) 1607-8454
    ISSN 1024-5332 ; 1024-5340
    DOI 10.1080/16078454.2024.2347673
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Can we truly define 'Fitness' for CAR-T therapy in large B cell lymphoma patients?

    Chen, Andy I / Maziarz, Richard T

    Chinese clinical oncology

    2023  Volume 13, Issue 1, Page(s) 15

    MeSH term(s) Humans ; Receptors, Chimeric Antigen ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/pathology ; Immunotherapy, Adoptive
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2023-10-24
    Publishing country China
    Document type Journal Article
    ZDB-ID 2828547-5
    ISSN 2304-3873 ; 2304-3873
    ISSN (online) 2304-3873
    ISSN 2304-3873
    DOI 10.21037/cco-23-78
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients.

    De Sa, Hong / Maziarz, Richard T / Gandhi, Arpita P

    Expert opinion on biological therapy

    2024  Volume 24, Issue 3, Page(s) 139–146

    Abstract: Introduction: The success of an allogeneic hematopoietic stem cell transplantation (alloHCT) is measured by cure from the underlying malignancy, immune reconstitution (IR), and freedom from graft-versus-host disease, without the continued need for ... ...

    Abstract Introduction: The success of an allogeneic hematopoietic stem cell transplantation (alloHCT) is measured by cure from the underlying malignancy, immune reconstitution (IR), and freedom from graft-versus-host disease, without the continued need for immunosuppressive therapy.
    Areas covered: Effective IR is critical to the success of alloHCT wherein poor IR can potentially increase the risk of infection and disease relapse. Different stem cell sources give rise to varying patterns of IR. Particularly with umbilical cord blood transplant, delayed IR is commonly seen with associated increased infection rates and non-relapse mortality, attributable to low CD34+ cell doses and predominance of naïve T cells in the graft. Recent FDA approval of omidubicel, an expanded cord blood graft, was granted due to rapid hematologic recovery and a reduced incidence of high-grade infections associated with improved IR. This review focuses on IR and infections seen with omidubicel and compares those to IR after alloHCT with other graft sources.
    Expert opinion: Characteristics of omidubicel, such as ready availability, high infused CD34+ cell dose, and rapid hematologic and immune recovery improve upon the shortcomings of standard umbilical cord blood transplantation. We feel that the data support the emergence of omidubicel as an alternative donor product.
    MeSH term(s) Humans ; Fetal Blood ; Immune Reconstitution ; Cord Blood Stem Cell Transplantation/adverse effects ; Transplantation, Homologous/adverse effects ; Hematopoietic Stem Cell Transplantation/adverse effects ; Graft vs Host Disease/etiology
    Language English
    Publishing date 2024-03-14
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2024.2326169
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL.

    Maziarz, Richard T / Gauthier, Jordan

    Nature reviews. Clinical oncology

    2022  Volume 20, Issue 1, Page(s) 5–6

    MeSH term(s) Humans ; Immunotherapy, Adoptive ; Antigens, CD19 ; Lymphoma, Large B-Cell, Diffuse
    Chemical Substances Antigens, CD19
    Language English
    Publishing date 2022-11-12
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-022-00711-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: A new beginning: can omidubicel emerge as the next, viable alternative donor source?

    Gandhi, Arpita P / Newell, Laura F / Maziarz, Richard T

    Therapeutic advances in hematology

    2023  Volume 14, Page(s) 20406207231192146

    Abstract: Umbilical cord blood (UCB) transplantation (CBT) has been an important alternative donor option for patients lacking matched related donor (MRD) or unrelated donor (URD) grafts. Only 30% of patients with high-risk hematologic malignancies have a human ... ...

    Abstract Umbilical cord blood (UCB) transplantation (CBT) has been an important alternative donor option for patients lacking matched related donor (MRD) or unrelated donor (URD) grafts. Only 30% of patients with high-risk hematologic malignancies have a human leukocyte antigen (HLA)-identical sibling; subjects without a MRD option are referred for HLA-matched URD selection, or utilize alternative donor sources such as HLA-mismatched URD, UCB, or haploidentical donor grafts. While CBT demonstrates an excellent graft-
    Language English
    Publishing date 2023-08-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2585183-4
    ISSN 2040-6215 ; 2040-6207
    ISSN (online) 2040-6215
    ISSN 2040-6207
    DOI 10.1177/20406207231192146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The evolving need for patient reported outcome data in determining choice of immune therapy treatment.

    Saultz, Jennifer / Maziarz, Richard T

    Med (New York, N.Y.)

    2020  Volume 2, Issue 8, Page(s) 907–911

    Abstract: Cellular therapy has changed the cancer treatment landscape and potential associated toxicities. The traditional short-term toxicities of chemotherapy-induced nausea, vomiting, and diarrhea are replaced by complex immune activation syndromes and ... ...

    Abstract Cellular therapy has changed the cancer treatment landscape and potential associated toxicities. The traditional short-term toxicities of chemotherapy-induced nausea, vomiting, and diarrhea are replaced by complex immune activation syndromes and immunologic organ-specific toxicities. Understanding the long-term consequences and impact of these therapies on patient quality of life is necessary.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Humans ; Nausea/chemically induced ; Patient Reported Outcome Measures ; Quality of Life ; Vomiting/chemically induced
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2020-07-04
    Publishing country United States
    Document type Journal Article
    ISSN 2666-6340
    ISSN (online) 2666-6340
    DOI 10.1016/j.medj.2021.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Mesenchymal stromal cells: potential roles in graft-versus-host disease prophylaxis and treatment.

    Maziarz, Richard T

    Transfusion

    2016  Volume 56, Issue 4, Page(s) 9S–14S

    MeSH term(s) Clinical Trials, Phase III as Topic/methods ; Clinical Trials, Phase III as Topic/statistics & numerical data ; Graft vs Host Disease/prevention & control ; Humans ; Mesenchymal Stem Cell Transplantation/methods ; Mesenchymal Stem Cell Transplantation/statistics & numerical data ; Mesenchymal Stem Cell Transplantation/utilization ; Mesenchymal Stromal Cells/cytology ; Mesenchymal Stromal Cells/physiology ; Primary Prevention/methods ; Transplantation Conditioning/methods
    Language English
    Publishing date 2016-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.13563
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top